A DDI value below 50 substantially increased the likelihood of death in IPF, outperforming traditional GAP components in prognostic accuracy. In prognosis calculations for patients with idiopathic ...

Chronic obstructive pulmonary disease (COPD) remains one of the leading causes of death worldwide, accounting for over three million deaths each year, according to the World Health Organization. Given ...

1 Mayo Clinic, Division of Cardiovascular Diseases, Scottsdale, AZ, United States 2 Mayo Clinic, Division of Cardiovascular Diseases, Rochester, MN, United States Introduction: The lingering ...

Breathing is an activity that you don't think about, until it becomes hard. With increasing pollution, smoking and rising lung cancer cases in India, it’s time we paid more attention to our lungs.

A 2% decline in FVC or DLco significantly increases the risk of death or lung transplant in IPF patients, challenging current clinical thresholds. The study suggests that smaller declines in lung ...

Background Lung function testing remains a cornerstone in the assessment and management of interstitial lung disease (ILD) patients. The clinical implications of the Global Lung function Initiative ...

If your doctor needs to figure out why you're having trouble breathing or to check for other lung problems, they may suggest lung diffusion testing. It measures how well your lungs are working. Lung ...

If approved, Molbreevi could be the first FDA-approved treatment for patients with autoimmune pulmonary alveolar proteinosis, a rare lung disease. Pharmaceutical company Savara has initiated a rolling ...

Since 2010, Juliana has been a professional writer in the technology and small business worlds. She has both journalism and copywriting experience and is exceptional at distilling complex concepts ...

The latest trial study from Savara Inc (NASDAQ:SVRA) met its primary endpoint. The company released results from Phase 3 IMPALA-2 trial of molgramostim 300 mcg administered once daily by inhalation ...